TEL AVIV, Israel & PARSIPPANY, N.J.--(BUSINESS WIRE)--Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced the publication of efficacy ...
LYN-005 is an investigational long-acting oral capsule formulation of the atypical antipsychotic risperidone. Positive data were announced from a phase 3 study comparing the pharmacokinetic (PK) ...
WATERTOWN, Mass.--(BUSINESS WIRE)--Lyndra Therapeutics ®, a clinical-stage biopharmaceutical company, today announced positive data from the STARLYNG-1 (LYN-005-C-301) study, comparing the ...
Teva announces positive real-world outcomes for UZEDY® and TEV-'749 in schizophrenia treatment, highlighting improved adherence and reduced hospital visits. Teva Pharmaceuticals has announced positive ...
BRISBANE, Calif., Nov. 16, 2023 /PRNewswire/ -- Delpor, Inc. (Delpor), a clinical stage biopharmaceutical company that utilizes innovative technologies to develop once-yearly therapeutics for chronic ...
Please provide your email address to receive an email when new articles are posted on . Lyndra Therapeutics began dosing in a clinical trial of risperidone for schizophrenia and schizoaffective and ...
WASHINGTON, Aug 22 (Reuters) - Johnson & Johnson won U.S. approval to promote the drug Risperdal for treating schizophrenia and bipolar disorder in children and teenagers, officials said on Wednesday.
Bausch Health, Canada Inc., part of Bausch Health Companies Inc. (NYSE: BHC)(TSX: BHC), today announced that it has ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results